Bonesupport Holding AB (publ) (STO: BONEX) Q2 2025 Earnings | 07/15/2025

About this video

Bonesupport Holding AB (publ) (STO: BONEX) reported its Q2 2025 results on July 15, 2025, marking another quarter of robust expansion as the company cemented its position in the global orthobiologics market. Net sales surged 29% year-over-year to SEK 284.4 million (up 40% at constant exchange rates), driven by continued strong market penetration of CERAMENT G and other premium bone graft substitutes in North America, where segment sales grew 36%. In Europe and the Rest of the World (EUROW), sales gained 4% to SEK 48.8 million. Gross margin held steady at an impressive 92.3%, and adjusted operating profit jumped 73% to SEK 62.4 million. Diluted earnings per share nearly doubled to SEK 0.79, reflecting growing operational leverage as Bonesupport scaled its business. Key highlights this quarter include CERAMENT G sales in the US reaching SEK 178.9 million, exceptional customer growth, and new clinical studies strengthening the product’s evidence base. The company maintained a solid balance sheet, closing the quarter with SEK 309.7 million in cash and generating SEK 50 million in operating cash flow. Management underscored the successful execution of its US commercial strategy and ongoing investments in research, product development, and distributor expansion, while noting currency headwinds and a slightly slower, yet positive, pace of growth in European markets. Strategically, Bonesupport announced its planned entry into the North American spinal procedure market, targeting a December 2025 launch for CERAMENT BVF in posterolateral and interbody applications—an expansion that could open significant new revenue streams. Management highlighted pending regulatory developments, such as a proposed New Technology Add-on Payment (NTAP) for CERAMENT G and anticipated higher CMS reimbursement rates for orthopedic procedures in 2026. Alongside these commercial initiatives, the company announced the upcoming CEO transition: Torbjörn Sköld will take over from Emil Billbäck as Chief Executive Officer on September 1, 2025. Outlook: Fiscal 2025: Full-year constant currency sales growth expected to exceed 40% North America: Continued momentum for CERAMENT G and expansion into spine segment Europe & Rest of World: Ongoing recovery and focus on hospital contract wins and new clinical data Pending finalization of new US reimbursement and regulatory opportunities for key products Effective September 1, 2025, Torbjörn Sköld appointed CEO, signaling leadership continuity and strategic evolution About Inside Ticker: For more expert analysis and real-time updates on Bonesupport Holding AB (publ) (STO: BONEX) and other market movers, follow Inside Ticker and visit InsideTicker.com for in-depth reports, financial insights, and the latest news on leading companies. #Bonesupport #BONEX #Q22025 #Earnings #Orthobiologics #CERAMENTG #FinancialResults #RevenueGrowth #USMarket #SpineMarket #GrossMargin #OperatingProfit #CMS #NTAP #StockMarket #Investing #InsideTicker #MedTech #Innovation #ClinicalEvidence #ProductLaunch #MarketExpansion #Guidance #LeadershipTransition #CashFlow #Q2Results #Sweden #Healthcare #Profitability #ShareholderReturns